The U.S. District Court for the District of Delaware has issued a permanent injunction against Invitae and its subsidiary ArcherDx, ordering them to stop using products containing material patented by Natera.
The court made exceptions for ongoing clinical trials, updating old trials currently undergoing peer review, and limited quality-control use.
In May, a jury in the same district court awarded Natera $19.4 million in damages for royalties and lost profits in its ongoing suit against Invitae and ArcherDx for infringement.
The court found that Invitae and ArcherDx had infringed on three patents held by Natera in their personalized cancer monitoring (PCM) products. According to court documents, “Invitae has asserted that it is phasing out most of the use of its legacy PCM.”
In October, Tecan Genomics filed a patent infringement suit against Invitae and ArcherDx, along with Danaher’s subsidiary IDT.